Sıla Öksüz

14PUBLICATIONS
38CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersInnate immunityMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Sep 26, 2026
FOLFOX Plus Bevacizumab Rechallenge Versus Regorafenib as Third-Line Treatment in Metastatic Colorectal Cancer: The Role of the Oxaliplatin-Free Interval.

|Jul 15, 2026
Real-World Treatment Outcomes After Nivolumab Progression in BRAF-Negative Metastatic Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group.

|Mar 14, 2026
Impact of Peri-Immunotherapy Antibiotic Exposure on Survival Outcomes in Metastatic Renal Cell Carcinoma: A Real-World IMDC Risk-Stratified Analysis.

Sila Oksuz, Oguzcan Kinikoglu, Ugur Ozkerim

|Jan 28, 2026
Significance of CEA Dynamics and Systemic Inflammatory Markers in HER2-Positive Metastatic Colorectal Cancer Patients Undergoing First-Line Chemotherapy: A Real-World Cohort Study.

Ugur Ozkerim, Oguzcan Kinikoglu, Sila Oksuz

|Jan 27, 2026
Development of a Machine Learning-Based Prognostic Model Using Systemic Inflammation Markers in Patients Receiving Nivolumab Immunotherapy: A Real-World Cohort Study.

Ugur Ozkerim, Deniz Isik, Oguzcan Kinikoglu

|Oct 16, 2025
Triple-Negative Apocrine Carcinoma: Largest Cohort Highlights Unique Biology and Survival Advantage.

Tugba Basoglu, Ugur Ozkerim, Sila Oksuz

Pageof 3

Frequent Collaborators

13 joint publications

Oguzcan Kınıkoglu

13 joint publications

Deniz Işık

12 joint publications

Nedim Turan

12 joint publications

Hatice Odabas